National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Bempedoic acid (Nilemdo®) HTA ID: 20026a

Nilemdo® is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidemia, as an adjunct to diet:

▪ In combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or

▪ Alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated

 

NCPE Assessment Process Complete
Rapid review commissioned 15/06/2020
Rapid review completed 03/07/2020
Rapid Review outcome A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of bempedoic acid compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 06/07/2020
Pre submission consultation with Applicant 22/09/2020
Full HTA submission received from Applicant 30/04/2021
Preliminary review sent to Applicant 22/06/2021
NCPE assessment re-commenced 19/07/2021
Factual accuracy sent to Applicant 28/07/2021
NCPE assessment re-commenced 11/11/2021
NCPE assessment completed 16/11/2021
NCPE assessment outcome The NCPE recommends that bempedoic acid (Nilemdo®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments and that a managed access programme is introduced*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.